IMVTImmunovant, Inc.
Price
+106%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 5% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for IMVT today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Mixed
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies.
In the company’s own words · 10-K filed May 20, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 9, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026.Earnings release · press release
- May 20, 2026Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026.Earnings release · press release
- Feb 6, 2026Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.